Foghorn Therapeutics Inc. cash flow statement
In fiscal 2025, Foghorn Therapeutics Inc.'s operations generated −$86.1m of cash; it spent $50,000 on capital projects, leaving free cash flow of −$86.1m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −31 | −50 | 194 | −118 | −100 | −86 | −84 |
| Depreciation and amortisation | 1 | 3 | 3 | 3 | 3 | 3 | 2 |
| Stock-based pay | 3 | 8 | 14 | 16 | 12 | 10 | 10 |
| Capital spending | 16 | 3 | 1 | 1 | 1 | 0 | 0 |
| Free cash flow | −47 | −54 | 192 | −119 | −101 | −86 | −84 |
| Free cash flow after stock pay | −50 | −62 | 178 | −136 | −113 | −97 | −94 |
| Shares issued | — | — | — | 0 | 103 | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −21 | −25 | −24 | −21 | −19 | −22 | −25 | −18 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Stock-based pay | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −21 | −25 | −24 | −21 | −19 | −22 | −25 | −18 |
| Free cash flow after stock pay | −24 | −27 | −27 | −24 | −22 | −25 | −28 | −20 |
| Shares issued | 0 | 0 | 0 | 0 | 0 | — | 50 | 0 |
Compare with peers
- Nanobiotix S.a. cash flow
- Zymeworks Inc. cash flow
- Cue Biopharma, Inc. cash flow
- C4 Therapeutics, Inc. cash flow
- Bioharvest Sciences Inc. cash flow
Head to head: FHTX vs NBTXFHTX vs ZYMECUE vs FHTXCCCC vs FHTX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies